Loading
A phase 1/2 trial of gemcitabine, capecitabine and sintilimab in pancreatic cancer, run by Zhejiang University, not yet recruiting.
Personalized Tumor Neoantigen MRNA Therapy Adjuvant Treatment for Postoperative Pancreatic Cancer. is a phase 1/2, interventional study registered as NCT06888674 by Zhejiang University, with a registry enrolment figure of 60 participants, started 2025-04-01 and due to reach its primary completion in 2027-04-01. Interventions recorded: individualized anti-tumor new antigen iNeo-Vac-R01 injection; Gemcitabine + Capecitabine; Sintilimab injection. Conditions listed: Pancreatic Cancer Resectable. Primary outcome: Occurence and frequence of AE and SAE. Pancreatic eligibility wording from the registry: "* Diagnosed with resectable pancreatic cancer as assessed per the 2024 NCCN Clinical Practice Guidelines and willing to undergo radical surgery;". Sites: China. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Sintilimab, Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Gemcitabine and the tag pancreatic-deep-dive.
Shares Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Gemcitabine, Cytotoxic chemotherapy and the tag pancreatic-deep-dive.
Shares Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Gemcitabine, Cytotoxic chemotherapy and the tag pancreatic-deep-dive.
Shares Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Gemcitabine, Cytotoxic chemotherapy and the tag pancreatic-deep-dive.
Shares Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Capecitabine, Gemcitabine and the tag pancreatic-deep-dive.
Shares Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Capecitabine, Gemcitabine and the tag pancreatic-deep-dive.
Shares Sintilimab, Pancreatic cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy, Immune checkpoint inhibitors and the tag pancreatic-deep-dive.
Shares Sintilimab, Pancreatic cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy, Immune checkpoint inhibitors and the tag pancreatic-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/